TP53 and non-small cell lung carcinoma: While AZD7762 reversed cisplatin resistance in NSCLC cell lines, independently of their p53 status [74] potentiation of cisplatin cytotoxicity in neuroblastoma cell lines was only seen in those that were G1 checkpoint defective (by p53 mutation, MDM2 amplification or p14 deletion) [75].